| Bioactivity | Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron[1]. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect[2]. |
| Target | IC50: 7.0 μM (dopamine D2 receptor) |
| In Vivo | Tipepidine (i.p.; 10-40 mg/kg; 0.5-23 hours) significantly decreases the immobility time in the forced swimming test in ACTH-treated rats. Tipepidine (i.p.; 40 mg/kg) increases the extracellular dopamine level of the nucleus accumbens (NAc) in ACTH-treated rats[2]. Animal Model: |
| Name | Tipepidine |
| CAS | 5169-78-8 |
| Formula | C15H17NS2 |
| Molar Mass | 275.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hamasaki R, et al. Tipepidine activates VTA dopamine neuron via inhibiting dopamine D₂ receptor-mediated inward rectifying K⁺ current. Neuroscience. 2013 Nov 12;252:24-34. [2]. Kawaura K, et al. Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect in the forced swimming test in adrenocorticotropic hormone-treated rats. Behav Brain Res. 2016 Apr 1;302:269-78. |